vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and BOSTON OMAHA Corp (BOC). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $29.7M, roughly 1.5× BOSTON OMAHA Corp). BOSTON OMAHA Corp runs the higher net margin — -23.1% vs -23.3%, a 0.2% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs 6.4%). Over the past eight quarters, BOSTON OMAHA Corp's revenue compounded faster (7.8% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Boston Omaha Corporation is a publicly traded diversified holding company. Its core operating segments include outdoor advertising, surety insurance, residential real estate development, and fixed wireless broadband services, primarily serving customers across the United States, with a focus on driving long-term shareholder value via strategic acquisitions and organic operational growth.

AMRN vs BOC — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.5× larger
AMRN
$45.1M
$29.7M
BOC
Growing faster (revenue YoY)
AMRN
AMRN
+0.6% gap
AMRN
7.0%
6.4%
BOC
Higher net margin
BOC
BOC
0.2% more per $
BOC
-23.1%
-23.3%
AMRN
Faster 2-yr revenue CAGR
BOC
BOC
Annualised
BOC
7.8%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
BOC
BOC
Revenue
$45.1M
$29.7M
Net Profit
$-10.5M
$-6.9M
Gross Margin
64.0%
Operating Margin
35.5%
-4.2%
Net Margin
-23.3%
-23.1%
Revenue YoY
7.0%
6.4%
Net Profit YoY
33.0%
-228.1%
EPS (diluted)
$-0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
BOC
BOC
Q1 26
$45.1M
Q4 25
$49.2M
$29.7M
Q3 25
$49.7M
$28.7M
Q2 25
$72.7M
$28.2M
Q1 25
$42.0M
$27.7M
Q4 24
$62.3M
$27.9M
Q3 24
$42.3M
$27.7M
Q2 24
$67.5M
$27.1M
Net Profit
AMRN
AMRN
BOC
BOC
Q1 26
$-10.5M
Q4 25
$-1.2M
$-6.9M
Q3 25
$-7.7M
$-2.6M
Q2 25
$-14.1M
$-2.3M
Q1 25
$-15.7M
$-669.3K
Q4 24
$-48.6M
$5.3M
Q3 24
$-25.1M
$-1.6M
Q2 24
$1.5M
$-2.2M
Gross Margin
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
47.1%
64.0%
Q3 25
44.7%
66.2%
Q2 25
69.2%
66.1%
Q1 25
59.8%
67.3%
Q4 24
-15.4%
69.5%
Q3 24
38.5%
67.5%
Q2 24
63.4%
68.2%
Operating Margin
AMRN
AMRN
BOC
BOC
Q1 26
35.5%
Q4 25
-12.9%
-4.2%
Q3 25
-22.4%
-3.7%
Q2 25
-22.0%
-2.9%
Q1 25
-39.9%
-2.9%
Q4 24
-84.3%
-4.6%
Q3 24
-59.5%
-2.7%
Q2 24
-0.8%
-16.2%
Net Margin
AMRN
AMRN
BOC
BOC
Q1 26
-23.3%
Q4 25
-2.5%
-23.1%
Q3 25
-15.6%
-9.0%
Q2 25
-19.4%
-8.2%
Q1 25
-37.4%
-2.4%
Q4 24
-78.0%
19.1%
Q3 24
-59.4%
-5.8%
Q2 24
2.3%
-8.3%
EPS (diluted)
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
$0.00
$-0.23
Q3 25
$-0.02
$-0.08
Q2 25
$-0.03
$-0.07
Q1 25
$-0.04
$-0.02
Q4 24
$-0.12
$0.17
Q3 24
$-0.06
$-0.05
Q2 24
$0.00
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
BOC
BOC
Cash + ST InvestmentsLiquidity on hand
$307.8M
$56.8M
Total DebtLower is stronger
$25.7M
Stockholders' EquityBook value
$516.1M
Total Assets
$645.8M
$713.1M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
BOC
BOC
Q1 26
$307.8M
Q4 25
$302.6M
$56.8M
Q3 25
$286.6M
$67.6M
Q2 25
$298.7M
$68.6M
Q1 25
$281.8M
$69.2M
Q4 24
$294.2M
$73.2M
Q3 24
$305.7M
$58.6M
Q2 24
$306.7M
$53.1M
Total Debt
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
$25.7M
Q3 25
$25.9M
Q2 25
$26.1M
Q1 25
$26.3M
Q4 24
$26.5M
Q3 24
$26.7M
Q2 24
$26.9M
Stockholders' Equity
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
$459.3M
$516.1M
Q3 25
$458.9M
$528.4M
Q2 25
$464.9M
$531.0M
Q1 25
$473.7M
$533.3M
Q4 24
$486.2M
$532.8M
Q3 24
$531.4M
$527.7M
Q2 24
$551.9M
$530.5M
Total Assets
AMRN
AMRN
BOC
BOC
Q1 26
$645.8M
Q4 25
$670.8M
$713.1M
Q3 25
$659.8M
$721.4M
Q2 25
$670.1M
$730.6M
Q1 25
$655.7M
$730.8M
Q4 24
$685.3M
$728.3M
Q3 24
$750.6M
$711.9M
Q2 24
$799.9M
$723.1M
Debt / Equity
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
0.05×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.05×
Q3 24
0.05×
Q2 24
0.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
BOC
BOC
Operating Cash FlowLast quarter
$17.9M
Free Cash FlowOCF − Capex
$-10.0M
FCF MarginFCF / Revenue
-33.8%
Capex IntensityCapex / Revenue
93.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
$15.3M
$17.9M
Q3 25
$-12.7M
$4.9M
Q2 25
$16.6M
$4.6M
Q1 25
$-12.5M
$2.6M
Q4 24
$-13.3M
$21.2M
Q3 24
$-2.4M
$5.2M
Q2 24
$-2.7M
$4.5M
Free Cash Flow
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
$-10.0M
Q3 25
$-489.4K
Q2 25
$-2.7M
Q1 25
$-4.3M
Q4 24
$-11.0M
Q3 24
$-1.2M
Q2 24
$-4.3M
FCF Margin
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
-33.8%
Q3 25
-1.7%
Q2 25
-9.7%
Q1 25
-15.5%
Q4 24
-39.2%
Q3 24
-4.4%
Q2 24
-15.9%
Capex Intensity
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
93.9%
Q3 25
18.9%
Q2 25
25.9%
Q1 25
24.7%
Q4 24
115.3%
Q3 24
23.2%
Q2 24
32.6%
Cash Conversion
AMRN
AMRN
BOC
BOC
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
3.97×
Q3 24
Q2 24
-1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

BOC
BOC

Billboard Rentals$11.9M40%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$10.0M34%
GIG$7.3M25%
Other$608.4K2%

Related Comparisons